Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
Tevogen Bio(US:TVGN) Globenewswire·2025-11-06 04:20This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patientsTVGN 489 utilizes off-the-shelf, genetically unmodified allogeneic T cellsTVGN 489 is designed to address both acute COVID-19 infection and Long COVID WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced a clinical milestone in ...